EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms

“A one-size-fits-all approach to biopharma R&D no longer fits the technology-savvy, diversified world of drug development.” In a newly published article in the DIA Global Forum, Mary Lynn Mercado (Novartis) and Madhavi Gidh-Jain (Sanofi) share their opinions about the evolving landscape of clinical trials, emphasizing TransCelerate's pivotal role in the collaborative partnership with EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms, which enabled adaptive platform trials through advanced tools and frameworks such as the master protocol template. The article also features perspectives from Peter M. (Novartis) and Cecile Spiertz (Exscientia) on the efforts and development of this protocol. Learn more about the TransCelerate and EU-PEARL collaboration: https://lnkd.in/efzuDWWS

📣 Read all about it! #c4c, represented by Prof. Carlo Giaquinto from Penta Foundation - Child Health Research, was mentioned in an article by Horizon Magazine! Click below to read about how Europe is advancing to try and improve #clinicaltrials 👩⚕️ ⚕ 🧒 https://lnkd.in/eAittReq #publication #HorizonEurope #EUfunding EFPIA - European Federation of Pharmaceutical Industries and Associations, EU Science, Research and Innovation, Innovative Health Initiative (IHI)

For the Rare Disease Moonshot, Rare Disease Day is everyday! We presented our efforts and progresses today at the International Congress on Rare Diseases & Orphan Drugs jointly organised by EURORDIS-Rare Diseases Europe and #RareDiseaseGreece What did we talk about?  1.     We identified gaps in the research, and we launch Research Needs Recommendations aiming to empower research funders to boost public private partnerships to enable R&D in white spots areas (with no research, no translational capabilities, and no solutions)  👉 https://lnkd.in/dQC7h2rV 2.     We leverage existing efforts, because so many of us are doing so much. We want to learn from them, to remove barriers for public private collaboration 👉 https://lnkd.in/dQuhtaFh 3.     We trigger new public private initiatives  👉 https://lnkd.in/dvXqKPww 4.     We collaborate to breaking silos between translational and clinical research players  👉 https://lnkd.in/dv7rHcKH 5.     We support advocacy all initiatives for the launch of an EU action plan for Rare Diseases  👉 https://lnkd.in/gGvaWNRz #rarediseaseayiseveryday #rarediseaseday EURORDIS-Rare Diseases Europe EFPIA - European Federation of Pharmaceutical Industries and Associations Critical Path Institute (C-Path) EATRIS BBMRI-ERIC ECRIN (European Clinical Research Infrastructure Network) european joint programme on rare diseases ejp rd EuropaBio - the European Association for Bioindustries EUCOPE - European Confederation of Pharmaceutical Entrepreneurs Accelerating Research & Development for Advanced Therapies (ARDAT) Screen4Care Together for Rare Diseases BGTC conect4children EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms 

Do you always wonder what public-private partnerships can do for white spots? 👏 to all involved Innovative Health Initiative (IHI) Children's Tumor Foundation EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms Global Coalition for Adaptive Research 📖 A must read https://lnkd.in/dqBEZiJs

🚀 Over 35 organisations from the public and private sectors joined forces in 2019 to advance platform trials in Europe. This innovative clinical trial methodology brings the promise of making clinical research more efficient and patient centric. EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms project is now closed and its main findings and learnings are summarised in a recent publication: "Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL". 🗣️This narrative review discusses the outlook for #platformtrials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. 🎯It concludes that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Read full publication here 👉 https://lnkd.in/dsVj9E9y 👥 You are welcome to join our vibrant community of practice and contribute to expand the use of platform trials in Europe and beyond. Please, get in touch 👉 https://lnkd.in/d697SB6J Franz Koenig Cecile Spiertz Daniel Millar Sarai Rodríguez Navarro Núria Machin Ann Van Dessel #JoanGenescà #JuanMPericàs Martin Posch  EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms Consortium Innovative Health Initiative (IHI); Medizinische Universität Wien The Janssen Pharmaceutical Companies of Johnson & Johnson Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca Teamit